Amanta Healthcare IPO has so far been booked more than 6 times on day 2; GMP slides to GMP at 12%. Do you have to bid?

The RS 126 Crore Initial Public Offer (IPO) from Amanta Healthcare was subscribed to the second day of BIKEN 6.28 times, largely powered by strong participation of the retail trade. In the Gray Market, the shares are currently trading with a premium of 12% above the upper price band of RS 126. Although slightly lower than the premium of yesterday, this still suggests potential statement profits. The subscription window will be concluded on 3 September.

Amana Healthcare IPO GMP today

Amanta Healthcare shares recommend a premium of 12% on the gray market on the top of the IPO prize band, set at RS 126 per share, a sign of positive investor sentiment prior to the offer.

Note: The Gray Market Premium (GMP) represents the unofficial premium in which IPO shares act before their official list. Although it reflects market expectations and potential quotations, it is not a regulated or guaranteed indicator.

Amanta Healthcare IPO subscription status:

On the second day of BIJK, the IPO from Amanta Healthcare received an enthusiastic response, with general subscriptions of 6.28 times the total shares offered.

Retail individual investors (RIIs) were the most active and applied for 8.86 times the 35 Lakh shares assigned to them – the strong question of small and individual investors.

Non-institutional investors (NIIs), who generally include high-quality individuals and companies, subscribed to their quota of 15 Lakh shares 8.59 times.

The question of qualified institutional buyers (QIBs) – such as investment funds, insurance companies and foreign institutional investors -, on the other hand, was relatively filled in, with only 4% of the 20 LAKH shares that are subscribed to them on day 1.

Amanta Healthcare IPO -Details:

The IPO will remain open for three days and closes on Wednesday 3 September. Ahmedabad established Amanta Healthcare is a pharmaceutical company that specializes in the production of sterile liquid formulations and medical devices. The company has established a price band of RS 120-126 per share for the offer.

The IPO consists entirely of a new edition of 1 Crore stock shares. The shares are expected to be mentioned on both the BSE and NSE on 8 September.

About the company

Amanta Healthcare focuses on the development and marketing of sterile injectables, IV fluids, ophthalmic solutions, respiratory care products, irrigation solutions and medical devices. The nuclear technology platforms include Steriport (ISBM) and ABFS (Aseptic Blow-Fill-Seal).

The company has built up a strong domestic presence with a network of more than 320 distributors and stockists, while also exporting to regions such as Africa, Latin -America, the UK and other emerging markets. In FY25, the domestic brand generics accounted for around 55% of its turnover, followed by 33% of the international turnover and 10% of product partnerships and contract production.

The production facility of Amanta in Hariyala, Gujarat, is equipped with seven production lines for both parenterals with large volume (LVPs) and Small Volume Parenterals (SVPs), and is certified by regulatory authorities in India and various international markets.

Financial

Amanta Healthcare achieved a consolidated income from RS 274.7 Crore in FY25, a marginal decline of RS 280.3 Crore in FY24. Despite the turnover dip, the company registered a strong improvement in profitability, with profit after the tax that increases sharply to RS 10.5 Crore in FY25, against RS 3.6 Crore in the previous tax year.

IPO objectives

The company plans to use RS 70 Crore from the IPO yield to expand its steriport production line, RS 30.1 Crore to set up a new production line for Small Volume Parenterals (SVPs), and the remaining funds will be allocated for general business purposes.

Do you have to subscribe?

Investor4edu has recommended to subscribe to the IPO, which emphasizes the strong potential of Amanta Healthcare to take advantage of the increasing demand for sterile liquid pharmaceutical and medical devices in both domestic and international markets.

At the top of the price band, the stock is valued at about 47 times the FY25 income after the edition, which suggests that the IPO is reasonably priced.

With certifications in more than 120 areas of law, a broad product portfolio and a strategic focus on sterile pharmaceutical products, Amanta Healthcare seems well positioned for continuous growth. Investor sentiment In the next two days, together with gray market trends, will offer further clarity prior to the offer of the shares.

((Indemnification: Recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)